EZH2 gain is also considered a negative prognostic factor in lung cancer as it promotes proliferation, invasion, and metastasis through the transcriptional repression of target genes such as CDKN2A. EZH2 is a target of miR-101 [157], with loss of miR-101 resulting in derepression of EZH2 expression, and providing yet another mechanism of EZH2 activation. The gene discussed is EZH2; the disease is lung cancer.